Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC

ONCOLYTICS BIOTECH INC

Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
Objective response rate 33% with pelareorep+FOLFIRI+bevacizumab, tripling the 6-11% standard of care.
Company actively engaging FDA to support potential accelerated approval pathway in this indication.
REO 022 study continues enrollment in randomized Phase 2 for 2L RAS-mutant MSS mCRC.
Data highlight durable benefit in a difficult-to-treat colorectal cancer population with few options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.